Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.

Experimental hematology - 1 Aug 2016

Botezatu Lacramioara, Michel Lars C, Helness Anne, Vadnais Charles, Makishima Hideki, Hönes Judith M, Robert François, Vassen Lothar, Thivakaran Aniththa, Al-Matary Yahya, Lams Robert F, Schütte Judith, Giebel Bernd, Görgens André, Heuser Michael, Medyouf Hind, Maciejewski Jaroslaw, Dührsen Ulrich, Möröy Tarik, Khandanpour Cyrus

Abstract excerpt

Epigenetic changes can contribute to development of acute myeloid leukemia (AML), a malignant disease of the bone marrow. A single-nucleotide polymorphism of transcription factor growth factor independence 1 (GFI1) generates a protein with an asparagine at position 36 (GFI1(36N)) instead of a serine at position 36 (GFI1(36S)), which is associated with de novo AML in humans. However, how GFI1(36N) predisposes to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Bone Marrow Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Immunophenotyping

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 27216773
DOI: 10.1016/j.exphem.2016.05.004

Genes

GFI1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.PMID 27216773Read ↗

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.Semantic proximity Read ↗

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapySemantic proximity Read ↗

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice.Semantic proximity Read ↗

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.Semantic proximity Read ↗

Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in miceSemantic proximity Read ↗

Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signatureSemantic proximity Read ↗

Dose-dependent role of Gfi1 in murine hematopoietic stem cell self-renewal and differentiationSemantic proximity Read ↗

A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.Semantic proximity Read ↗

Characterization of a genomic region 8 kb downstream of GFI1B associated with myeloproliferative neoplasms.Semantic proximity Read ↗

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaSemantic proximity Read ↗

Mutations in growth factor independent-1 associated with human neutropenia block murine granulopoiesis through colony stimulating factor-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.